A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
High Resolution Image Download MS PowerPoint Slide Inhibition of inflammasome and pyroptotic pathways are promising strategies for clinical treatment of autoimmune and inflammatory disorders. MCC950, a potent inhibitor of the NLR-family inflammasome pyrin domain-containing 3 (NLRP3) protein, has shown encouraging results in animal models for a range of conditions; however, until now, no off-targets have been identified. Herein, we report the design, synthesis, and application of a novel photoaffinity alkyne-tagged probe for MCC950 ( IMP2070 ) which shows direct engagement with NLRP3 and inhibition of inflammasome activation in macrophages. Affinity-based chemical proteomics in live macrophages identified several potential off-targets, including carbonic anhydrase 2 (CA2) as a specific target of IMP2070, and independent cellular thermal proteomic profiling revealed stabilization of CA2 by MCC950. MCC950 displayed noncompetitive inhibition of CA2 activity, confirming carbonic anhydrase as an off-target class for this compound. These data highlight potential biological mechanisms through which MCC950 and derivatives may exhibit off-target effects in preclinical or clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Biochemical validation of MCC950 as a noncompetitive inhibitor of carbonic anhydrase 2 (CA2). (a) Residual esterase enzyme activity of CA2 when treated with MCC950. Error bars represent SEM, N = 3. IC50 = 11 μM; slope = −1.47, R2 = 0.99. (b) Hanes-Woolf plot assessing CA2 (85 nM) esterase activity in the presence of MCC950 (1–100 μM) and p-NPA (0.125–1 mM). Error bars represent SEM, N = 3. (Slope, R2) for each MCC950 concentration: 100 μM (3.17, 0.94); 40 μM (9.51, 0.95); 16 μM (20.19, 0.96); 6.4 μM (26.55, 0.95); 2.56 μM (31.74, 0.96); 1.02 μM (33.59, 0.95); DMSO (29.03, 0.96). (c) Molecular docking of MCC950 against CA2 (PDB 3QYK) predicted MCC950 (cyan) interactions with the catalytic zinc (gray), and occupation of the protein pocket similar to 4-(7-methylpyrazolo[3′,4′:4,5]thiopyrano[2,3-b]pyridin-1(4H)-yl)benzenesulfonamide (green). Oxygens are shown in red, sulfur in yellow, and nitrogen in dark blue. (d) Predicted interactions between MCC950 (black) and CA2 residues (blue) and zinc (gray).](https://figures.cochat.ai/paper-figures/6fe391e7cfb34b4b870889168388c88f/a-probe-for-nlrp3-inflammasome-inhibitor-mcc950-identifies-carbonic-anhydrase-2-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
FSP1 is a glutathione-independent ferroptosis suppressor
Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., et al. (2019) · Nature · doi:10.1038/s41586-019-1707-0 · Cited by 3,341
Self-citationCarbonic anhydrases: novel therapeutic applications for inhibitors and activators
Supuran, C. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2467 · Cited by 3,192
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820
Esterase Activities of Human Carbonic Anhydrases B and C
Verpoorte, J. A., Mehta, S., & Edsall, J. T. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95800-x · Cited by 1,064
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
Coll, R. C., Hill, J. R., Day, C. J., Zamoshnikova, A., Boucher, D., Massey, N. L., Chitty, J. L., Fraser, J. A., Jennings, M. P., Robertson, A. A. B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0277-7 · Cited by 1,014
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571
Cited by
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Coll, R. C., Schroder, K., & Pelegrín, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.003 · Cited by 755
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Vande Walle, L., & Lamkanfi, M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00822-2 · Cited by 350
Targeting the NLRP3 inflammasome for inflammatory disease therapy
Cabral, J. E., Wu, A., Zhou, H., Pham, M. A., Lin, S., & McNulty, R. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.04.007 · Cited by 200
Photoaffinity labelling strategies for mapping the small molecule–protein interactome
Burton, N. R., Kim, P., & Backus, K. M. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob01353j · Cited by 114
Hu, X., Shen, Y., Zhao, Y., Wang, J., Zhang, X., Tu, W., Kaufman, W., Feng, J., & Gao, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767508 · Cited by 56
The role of NLRP3 inflammasome in sepsis: A potential therapeutic target
He, W., Dong, H., Wu, C., Zhong, Y., & Li, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109697 · Cited by 58
Nanobodies dismantle post‐pyroptotic ASC specks and counteract inflammation in vivo
Bertheloot, D., Wanderley, C. W. S., Schneider, A. H., Schiffelers, L. D. J., Wuerth, J. D., Tödtmann, J. M. P., Maasewerd, S., Hawwari, I., Duthie, F., Rohland, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115415 · Cited by 48
Grotemeyer, A., Fischer, J. F., Koprich, J. B., Brotchie, J. M., Blum, R., Volkmann, J., & Ip, C. W. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02759-0 · Cited by 48
Wahl, D., Risen, S. J., Osburn, S. C., Emge, T., Sharma, S., Gilberto, V. S., Chatterjee, A., Nagpal, P., Moreno, J. A., & LaRocca, T. J. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03182-9 · Cited by 44
Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors
Thapa, P., Upadhyay, S. P., Singh, V., Boinpelly, V. C., Zhou, J., Johnson, D. K., Gurung, P., Lee, E. S., Sharma, R., & Sharma, M. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100100 · Cited by 37
Haseeb, M., Javaid, N., Yasmeen, F., Jeong, U., Han, J. H., Yoon, J., Seo, J. Y., Heo, J.-K., Shin, H. C., Kim, M. S., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00831 · Cited by 31
NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development
Haque, I., Thapa, P., Burns, D. M., Zhou, J., Sharma, M., Sharma, R., & Singh, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116078 · Cited by 35
Wu, X., Yang, J., Wu, J., & Yang, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116261 · Cited by 32
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action
Wilhelmsen, K., Deshpande, A., Tronnes, S. U., Mahanta, M., BANICKI, M., COCHRAN, M., Cowdin, S., Fortney, K., Hartman, G. D., Hughes, R. E., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20242403 · Cited by 23
Sabra, M. S., Hemida, F. K., & Allam, E. A. H. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03427-4 · Cited by 30
Abietane diterpenoids from Orthosiphon wulfenioides with NLRP3 inflammasome inhibitory activity
Tu, W., Zhao, Y.-X., Yang, C.-L., Zhang, X., Li, X.-L., Sakah, K.-J., Zhang, R., Xiao, W., & Liu, M. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106534 · Cited by 16
Chung, C., Kao, Y., Chen, Y., Lin, Y., Higa, S., Hsu, K., & Chen, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051921 · Cited by 16
Therapeutic role of NLRP3 inflammasome inhibitors against Alzheimer’s disease
Tantra, T., A, A. R. T., Nandini, N., & Chaudhary, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107912 · Cited by 15
Zhao, H., Kumar, P., Sobreira, T. J. P., Smith, M. L., Novick, S. J., Johansson, A., Łuchniak, A., Zhang, A. X., Woollard, K. J., Larsson, N., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00777 · Cited by 13
Exploring novel non-opioid pathways and therapeutics for pain modulation
Alessi, I. G., Banton, K. L., Sliter, J., Zaw-mon, C., Lascano, C. H. P., Ryznar, R. J., & Bar‐Or, D. (2025) · Molecular Pain · doi:10.1177/17448069251327840 · Cited by 13
Structure–Stability Relationship of NLRP3 Inflammasome-Inhibiting Sulfonylureas
Keuler, T., Ferber, D., Marleaux, M., Geyer, M., & Gütschow, M. (2022) · ACS Omega · doi:10.1021/acsomega.2c00125 · Cited by 13
Albright, J. M., & Holian, A. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf140 · Cited by 12
Yang, F., Dai, Z., Xue, M.-Y., Chen, X.-Y., Liu, J., Li, W., Xu, L., & Di, B. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00343 · Cited by 13
Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency
Walle, L. V., Said, M. S., Paerewijck, O., Bertoni, A., Gattorno, M., Linclau, B., & Lamkanfi, M. (2024) · Life Science Alliance · doi:10.26508/lsa.202402644 · Cited by 13
Tu, W., Zhang, X., Zhao, Y.-X., Chen, W., Zhang, X.-Y., Yang, C.-L., Zeb, M. A., Li, X., Sakah, K.-J., Zhang, R., et al. (2023) · Organic Chemistry Frontiers · doi:10.1039/d3qo00247k · Cited by 11
Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus
Nnolum-Orji, N. F., Kumar, P., Ngema, L. M., & Choonara, Y. E. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104456 · Cited by 13
Sharma, A., Cipriano, M. J., Ferrins, L., Hajduk, S. L., & Mensa‐Wilmot, K. (2022) · iScience · doi:10.1016/j.isci.2022.105302 · Cited by 9
Baglini, E., Ravichandran, R., Berrino, E., Salerno, S., Barresi, E., Marini, A. M., Viviano, M., Castellano, S., Settimo, F. D., Supuran, C. T., et al. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1956913 · Cited by 8
Gao, S., Li, N., Lin, Z., Zhong, Y., Wang, Y., & Shen, X. P. (2024) · The FASEB Journal · doi:10.1096/fj.202301922rr · Cited by 8
Fawzy, M. N., Badawi, G. A., & El‐Sayed, R. M. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110704 · Cited by 6
Feng, H., Li, D., Zhu, F., Jiang, C., Su, M., Kong, Y., Zheng, Y., Yuan, Y., Huang, W., Chen, X., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129987 · Cited by 7
Target-Based Screening for Lead Discovery
Kesh, M., & Goel, S. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_7 · Cited by 7
Xu, Y., Blevins, H., Biby, S., Namme, J. N., Zhang, K., Li, R., & Zhang, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02163 · Cited by 8
Zhang, Y., Zhang, D., & Xiao, H. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261430002 · Cited by 7
Zhen, D., Liu, C., Sun, X., Bao, T., Wang, B., Zheng, K., Wu, Z., Chen, X., & Zhang, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1861169 · Cited by 7
Zhang, X., Wang, Q., Li, F., Li, S., Lin, H., & Huo, Y. (2023) · The Nephron journals/Nephron journals · doi:10.1159/000529212 · Cited by 5
Tan, Y., Fu, S., Yang, T., Xie, Y., Shen, G., Yan, J. R., Zhao, Y., & Ni, F. (2022) · Chemical Communications · doi:10.1039/d2cc03868d · Cited by 5
Alzarea, S. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-34068-2 · Cited by 4
Sharma, S., Wahl, D., Risen, S. J., Gilberto, V. S., Chatterjee, A., Moreno, J. A., LaRocca, T. J., & Nagpal, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.07.583991 · Cited by 4
Velatooru, L. R., Arroyave, E., Rippee‐Brooks, M. D., Burch, M., Yang, E., Zhu, B. D., Walker, D. H., Zhang, Y., & Fang, R. (2024) · Infection and Immunity · doi:10.1128/iai.00468-24 · Cited by 7
Zhi, Y., Chen, H., Huang, Y., Li, L., Chen, Z., Huang, H., Ke, F., Guo, Y., & Chen, C. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117458 · Cited by 6
Novel Optical Imaging Probe for the Targeted Visualization of NLRP3 Inflammasomes in Living Retina
Uddin, M. I., Dieckmann, B. W., & Soliman, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00999 · Cited by 4
Sen, D., Bisht, S., & Gupta, S. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00446-8 · Cited by 4
Li, G., Wang, Y., Zhang, Y., Kang, Z., & Zhao, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02338 · Cited by 4
The NLRP3 inflammasome as a key pathway in the affective and chronic fatigue symptoms of Long COVID
Zhang, Y., Al‐Hakeim, H. K., Al-Jassas, H. K., & Maes, M. H. J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07703-3 · Cited by 4
Exploring NLRP3 Inhibition as a Key Modulator in Neonatal Hypoxic-Ischemic Brain Injury
Mathias, K., Machado, R. S., Cardoso, T., Naspolini, B., Prophiro, J. S., & Petronilho, F. C. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08851-3 · Cited by 3
Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy
Zhang, W., Pei, B., Zhou, Y., Li, H., Ma, W., Zhou, B., Zhou, C. Y., Jiang, H., & Ji, X. (2025) · Aging and Disease · doi:10.14336/ad.2024.1688 · Cited by 8
Darbinian, E., Mlaga, K. D., Aranguren, M., Desjardins, A., Martineau, E., Massé, C., Leiding, J. W., Poudrier, J., & Falcone, E. L. (2025) · Blood · doi:10.1182/blood.2025029676 · Cited by 4
Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases
Tan, K., Rodríguez-Fernández, M. M., Keuler, T., Hansen, F. K., Gütschow, M., Weindl, G., & Marco, J. L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02657 · Cited by 4
Cannabidiol as a modulator of NLRP3 inflammasome: Mechanistic insights and therapeutic potential
Jaisankar, D., & Jayaprakash, N. (2026) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2026.05.003 · Cited by 2
Zhou, N., & Zhi, Y. (2025) · Diagnostics · doi:10.3390/diagnostics15243195 · Cited by 1
Eyolfson, E., Bettio, L. E. B., Brand, J., Gupta, N. K., Hamer, E., Salas, R., Kulkarni, A. A., & Christie, B. R. (2026) · Hippocampus · doi:10.1002/hipo.70072 · Cited by 1
Xiong, X., Zhang, R., Min, Z., Liu, J., Zheng, P., Li, X., & Min, Z.-L. (2024) · Research on Chemical Intermediates · doi:10.1007/s11164-024-05431-1 · Cited by 1
Alangode, A., Rajasekhar, A., Sabu, J. J., Krishna, S., Anuja, D., Sreeja, A., Remesh, G., Kaladevi, A., & Nair, B. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156830
Sabra, M. S., Hemida, F. K., & Allam, E. A. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2556098/v1
Sabra, M. S., Hemida, F. K., & Allam, E. A. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2594505/v1
Sabra, M. S., Hemida, F. K., & Allam, E. A. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2556098/v2
Zhang, R., Xiong, X., & Min, Z.-L. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099313497240514072445
McKenna, S. M., Florea, B. I., Zisterer, D. M., van Kasteren, S. I., & McGouran, J. F. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00053f
Wilhelmsen, K., Deshpande, A., Tronnes, S. U., Mahanta, M., BANICKI, M., COCHRAN, M., Cowdin, S., Fortney, K., Hartman, G. D., Hughes, R. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.21.629867
Singh, S., Gupta, N. K., Ahsan, A. U., Oladapo, A., Mata, L. O., Buch, S. J., Kulkarni, A. A., & Periyasamy, P. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153409
Haseeb, M. A., Choi, H., Jeong, U., Kim, M. S., & Choi, S. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151905 · Cited by 2
Martino, S. D., Giuffrè, M. R., Petri, G. L., Gulotta, M. R., Zichittella, C., Passalacqua, E., Barberi, G., Amico, P., Buscetta, M., Coronnello, C., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107533
Sandhu, J. K., Tanha, J., & Arbabi‐Ghahroudi, M. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671675 · Cited by 2
Rabiei, F., Askari, H., Vala, A., Mardazad, M., & Ghasemi‐Kasman, M. (2026) · Current Clinical Pharmacology · doi:10.2174/0127724328444835260407154423
You, C., Dong, Y., Zhang, D., Wang, T., Zhang, W., Zhao, X., & Sun, J. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10292-z
Date, A., Schuhmacher, A., Lü, J., Berezina, D., Tate, E. W., Barnard, A., & Houghton, J. W. (2026) · PROTEOMICS · doi:10.1002/pmic.70154 · Cited by 2
Self-citationRepurposing AZD-7762 as a novel direct NLRP3 inhibitor for the treatment of inflammatory diseases
Zong, L., Liu, X. W., Zheng, M., Zhang, J., & He, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117053
Neutrophils From Aged Individuals Release NETs to Impair Oral Wound Healing Through NLRP3 Activation
Wang, D. C., Bai, F., Wang, Z., He, J., Li, H., Zhou, F. X., Chen, T., Xiang, L., Man, Y., & Wu, Y. (2026) · Oral Diseases · doi:10.1111/odi.70398
Smolarz, M., Pondel, N., Zając, G., Kurczyk, A., Pietrowska, M., Gawin, M., Dębiec, M., Małecki, A., Nowacka-Chmielewska, M. M., & Toborek, M. J. (2026) · Cells · doi:10.3390/cells15161443
Oxidative stress and glycosylation in viral infection and inflammatory response
Chakraborty, S., Kasirajan, A., & Pillai, A. B. (2026) · Advances in clinical chemistry · doi:10.1016/bs.acc.2026.08.005
Decouty‐Pérez, C., Álvarez‐Rubal, M., Polo-Fernandez, I., Martínez-Cuevas, E., Ruiz, C., Fuertes-Yebra, E., Chioua, M., Diez‐Iriepa, D., Marco, J. L., Valencia, I., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00341
Raja, S., & Rani, J. (2026) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_108_26
Sharma, C., Sharma, S., Thakur, S., Rani, D., Gupta, S., & Mishra, M. K. (2026) · Cell Death · doi:10.1016/j.celld.2026.100027
Worawichitchaikun, T., Wantanachaisaeng, P., Teeppaibul, T., & Suwannalert, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198931
Κeramidas, P., Pitou, M., Aggeli, A., Varlamis, S., & Choli‐Papadopoulou, T. (2026) · FEBS Journal · doi:10.1111/febs.70763
Wang, Y., Du, J., Dong, E., & Sun, W. (2026) · Cells · doi:10.3390/cells15201895
Metadata
- Authors
- Kennedy, C. R., Goya Grocin, A., Kovačič, T., Singh, R., Ward, J. A., Shenoy, A. R., & Tate, E. W.
- Affiliations
- Imperial College London (GB)
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, United Kingdom
- The Francis Crick Institute (GB)
- Corresponding author
- Shenoy, Avinash R.
- Tate, Edward W.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-05-18
- Volume
- 16
- Issue
- 6
- Pages
- 982-990
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- PMC
- PMC8218299
- OpenAlex
- W3160057429
- Cited by
- 81
- References
- 33
- Citations by year
- 2026: 27 · 2025: 18 · 2024: 15 · 2023: 11 · 2022: 7 · 2021: 3
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Engineering and Physical Sciences Research Council (EP/L015498/1)
- Medical Research Council (MR/P022138/1)
- Wellcome Trust (108246/Z/15/Z)
- Cancer Research UK (C29637/A20183, C29637/A21451)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Keywords
- MCC950, NLRP3 inflammasome, carbonic anhydrase II, off-target effects, photoaffinity probes, chemoproteomics, macrophages, pyroptosis, non-competitive inhibition, drug target identification
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Cell Line, Enzyme Inhibitors, Furans, Humans, Indenes, Macrophages, Models, Molecular, Sulfonamides, Carbonic Anhydrase II, Proteomics, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.